*Purpose: Prior studies have shown that almost 50% of kidney transplant patients from hepatitis C Ab+/NAT – donors have seroconverted but its impact on renal allograft outcome has rarely been reported. We studied renal allograft outcomes in HCV AB+/NAT – donor kidney transplant patients with hepatitis C antibody seroconversion and without seroconversion.

*Methods: A retrospective review was conducted in 49 HCV NAT negative patients who received kidney transplant HCV Ab+/NAT – donors from 01/2017-11/2018. Patients received thymoglobulin induction and maintenance with tacrolimus, mycophenolate and prednisone. Patients were analyzed by dividing into 2 groups, seroconversion and no seroconversion group. Seroconversion was defined by patients who have HCV antibody negative converted to positive and no seroconversion group who were negative and remain negative after transplant. No patients in either group became viremic. Data were collected up to 12 months. Statistical significance was based on t test for continuous variables and chi square analyses for categorical variables.

*Results: We found that patients with hepatitis C antibody seroconversion received higher KDPI score kidneys and patients without seroconversion group had higher cPRA. Both groups of patient had no significant differences in serum Cr, eGFR, proteinuria, acute rejection, graft survival and patient survival rates at 12 months.

*Conclusions: 51% patients with Hepatitis C antibody positive/NAT negative donors have seroconverted but no significant difference was noted when compared to patients without seroconversion. Larger studies with longer follow up are required to confirm these findings

« Back to 2020 American Transplant Congress